Septerna Inc (NASDAQ: SEPN) is a clinical-stage biopharmaceutical company focused on drug discovery and development. The company generates no product revenue as of the filing date and funds operations through equity and debt financings, collaborations, strategic alliances, and licensing arrangements. Septerna completed its initial public offering in October 2024. The company recognizes revenue, when applicable, under ASC 606 through IP licenses and performance obligations tied to collaboration or licensing contracts. As a pre-revenue drug developer, it has accumulated a deficit and reported net losses through December 31, 2025. Leadership includes Chief Financial Officer Gil M. Labrucherie and Chairman Jeffrey Tong, Ph.D. The company operates under a capital structure reliant on external financing, with no disclosed debt-to-cash ratio in the available filing excerpts. Septerna has not yet generated substantial product revenue and expects to remain dependent on capital markets and partnership arrangements for the foreseeable future, per its 10-K filed March 9, 2026.

Revenue model

No product revenue disclosed as of December 31, 2025. Revenue recognition policy is structured under ASC 606, covering IP licenses and collaboration-based performance obligations. Financing has come from equity issuances, including an IPO in October 2024 and a Series B convertible preferred stock round.

Products and services

Drug discovery and development programs. No specific named drug candidates, approved products, or branded therapies are identified in the available filing excerpts.

Customers and end markets

No customer names, customer counts, or specific end markets are identified in the available filing excerpts. The company is pre-commercialization as of December 31, 2025.

Value-chain role

Early-stage drug developer. Revenue model, when applicable, includes IP licensing and collaboration agreements with performance obligations recognized over time or at a point in time under ASC 606.

Geographic exposure

U.S.-based operations. Filing references EU data protection regulations (GDPR, NIS 2) and cross-border data transfer requirements, indicating some exposure to EU regulatory frameworks, but no specific international revenue or operational footprint is disclosed.

Source: SEC 10-K, filed 2026-03-09

Industry: Pharmaceutical Preparations